Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

NHS funding and commissioning

NHS England to issue guidance on dropping ‘low priority’ drugs from NHS prescriptions

In a bid to save £128m, NHS England will be removing from prescription a number of popular drugs, foods and food supplements used to treat chronic conditions.

Shelves of gluten, dairy and nut free food on shelves in a Tesco store

Source: Stephen Barnes / Gluten Free / Alamy Stock Photo

Patients will no longer be able to get some gluten-free foods, necessary for life-long conditions such as coeliac disease, on prescription

NHS England has identified a number of medicines that should no longer be available on prescription in a move that would save the NHS £128m a year. The drugs have been included in the list because they are deemed to be “ineffective, unnecessary, inappropriate for prescription on the NHS” or because cheaper alternatives can be bought over the counter.

NHS England is working with clinical commissioning leads to develop national guidelines that will set out which products are to be dropped from prescription. The intention is for more products to be added to the list as part of an ongoing government review.

A spokesperson for NHS England says: “The increasing demand for prescriptions for medication that can be bought over the counter at relatively low cost, often for self-limiting or minor conditions, underlines the need for all healthcare professionals to work even closer with patients to ensure the best possible value from NHS resources, while eliminating waste and improving patient outcomes.”

The guidelines will give advice to clinical commissioning groups (CCGs) about which products are being taken off prescription, as well as providing support to prescribers and dispensers, it adds.

The plan to remove low-value drugs from NHS prescription is based on work carried out by NHS Clinical Commissioners (NHSCC) — the national group representing CCGs in England.

NHSCC identified potential savings of £400m a year by removing products that fall into four categories: low clinical value; cheaper alternatives available; clinically effective but ‘low priority’ and products prescribed on the NHS that can be bought over the counter (see ‘Medicines and products identified as ‘low priority’ for NHS prescribing’).

More details about the move are due to be revealed on 31 March 2017 when NHS England publishes its delivery plan for the ‘Five year forward view’, which sets out its reforms for the health service up until 2020.

Graham Jackson, co-chair of NHSCC, says: “We need to be honest with the population — the NHS can and does provide high quality, cost-effective care, but our ability to continue to do so will be restricted if we can’t prioritise those areas which will get the best outcomes for patients, while getting the best value for our limited NHS budget.

“The medicines spend is one where there is huge potential to unlock resources and redirect them to those higher priority areas like mental health and primary care. Through doing this we can deliver better outcomes for patients. The principles of this work will also support the much needed long-term transformation of the NHS.”

He says NHSCC had identified “an initial £128m worth of products to kick off those discussions with the aim of agreeing that CCGs can begin to reduce their spending on these at a national level. We know that CCGs are keen to explore other products that promote the self-care agenda and where there are even more significant sums of money that could be released and used more effectively and efficiently for our patients and local populations”.

These products include antihistamines, sun creams, cough and cold remedies, heartburn and indigestion products.

Julie Wood, chief executive of NHS Clinical Commissioners, adds: “This is not about cutting essential services or restricting access for patients to services they need, it is about allowing local clinical leaders to make the best and most efficient use of the money CCGs have available to spend in really challenging circumstances.”

The Royal Pharmaceutical Society (RPS) and the Royal College of General Practitioners (RCGP), however, have expressed some concerns about the move.

Sandra Gidley, chair of the Royal Pharmaceutical Society English Pharmacy Board

Source: MAG/The Pharmaceutical Journal

Sandra Gidley, chair of the Royal Pharmaceutical Society English Pharmacy Board, is concerned about a blanket ban on products used to treat life-long conditions such as coeliac disease and chronic pain

Sandra Gidley, chair of the RPS English Pharmacy Board, says: “The NHS has traditionally provided treatment free at the point of use for both short-term and life-long conditions. Today’s announcement could be interpreted as an attack on this important principle. Balanced against this is the need for the NHS to be as cost effective as possible in a time of constrained resources. We understand the need for prioritisation.”

Gidley agrees that products with “low or no clinical evidence of effectiveness” should be urgently reviewed, but says she is surprised that “homeopathy, which has no scientific evidence of effectiveness is not on the list for review”.

She adds: “We are concerned at how a blanket ban of products to treat life-long conditions such as coeliac disease and chronic pain could have unintended consequences on those who rely on these treatments to improve the quality of life. For those on low incomes, ability to pay for products and medicines can be a significant barrier to accessing treatment.”

Similar reservations were expressed by Helen Stokes-Lampard, chair of the RCGP: “Imposing blanket policies on GPs that don’t take into account demographic differences across the country, or allow flexibility for a patient’s individual circumstances, risks alienating the most vulnerable in society — and we will be seeking assurances from NHS England that this won’t be the case.”

Box: Medicines and products identified as ‘low priority’ for NHS prescribing

Products with low clinical effectiveness or lack of evidence (total annual spend: £37.98m)

  • Co-proxamol (£8.32m)
  • Omega-3 and fish oils (£5.65m)
  • Lidocaine plasters (£17.58m)
  • Rubefacients (£6.43m)

Clinically effective products with a more cost-effective alternative (total annual spend: £58.69m)

  • Liothyronine (£30.93m)
  • Tadalafil (£10.51m)
  • Doxazosin MR (£7.12m)
  • Fentanyl (£10.13m)

Clinically effective products that are deemed low priority (total annual spend: £31.35m)

  • Some gluten-free foods (£21.88m)
  • Non-NHS funded travel vaccines (£9.47m)

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20202526

Readers' comments (2)

  • Detailed individualized responsive personal with respect for professional autonomy versus simplistic monolithic inflexible impersonal and dogmatic????? Which would you expect the GPs (who are in the "driving seat" in the CCGs that make up NHS CCs) to prefer???? There are undoubtedly hundreds and possibly thousands of people being prescribed drugs/products on the lists above for whom alternatives (including self-care or nothing) would be better or just as good. BUT....... some people may fare much better with some of the things on the lists - even if it is for really idiosyncratic and mysterious reasons. Who is best placed to make the required judgements? What are we to make of GPs leading CCGs throwing their hands up and effectively declaring that they and their colleagues would prefer a prohibition from on-high to having to make those judgements and have the required conversations?

    Unsuitable or offensive? Report this comment

  • The wastage of drugs must be looked at seriously before the cuts on the prescribing list is mentioned

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now
  • Drugs and the Liver

    Drugs and the Liver

    Drugs and the Liver assists practitioners in making pragmatic choices for their patients. It enables you to assess liver function and covers the principles of drug use in liver disease.

    £38.00Buy now
  • Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons

    Clarke's Analysis of Drugs and Poisons is the definitive reference source of analytical data for drugs and poisons.

    £535.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Shelves of gluten, dairy and nut free food on shelves in a Tesco store
  • Sandra Gidley, chair of the Royal Pharmaceutical Society English Pharmacy Board

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.